agree re r/s however move is possible if volume is there. a few years ago tgc ran to $3.
jsda indicated they were against r/s because of cost involved. speaking of low floaters i think atea is poised for a run based on expected q3 results. re comment about banks, if profits rise with rates then i assume the spread between what they loan money to customers and their borrowing costs rise because right now their borrowing costs are almost zero.
good post about palomino. re relocation greenwood village is less than 1/2 hr to denver and is home to over 20 oil and gas and related service companies. i also suggest that if anyone has concerns they call the company directly, they are responsive with the proviso that conversations do not get posted on the internet.
it replaces similar arrangement of May 7th, except this one is for 50M, last one for 40 M (not sure how much of last one was actually used) Last arrangement had little impact on price as it was announced when stock was near lower BB. Gradual at the market pricing is preferable to below market secondary. it also shows potential partner or acquirer that company has the means and strengthens negotiating posture. As indicated in earlier post MNKD had about 50% dilution as price went from 2's to 10. i added on friday and will add more on dips.
fewer shares than last year, but still large position. u may be right but it is priced accordingly - imo modest downside potential, still large upside potential. i still have long term view, looking for new highs next year with easier y to y comparisons on revenues, earnings and pps.
roche bought Seragon (P1 breast cancer drug) for 0.7 B upfront plus up to 1 B milestone payments (first day of run) then article (second day of run)/
its sounds like deal involves low revenue initially with potential for significant ramp up. market, in search of latest hot stock overreacted on runup but brought attention to the company. i am adding to position today
nip - ty for bringing SNTA to my attention. i notice that you seem to be trading it looking for rock bottom entry pts. if this is indeed another PCYC, it will step up in bursts, rather than linearly. If so aren't you afraid of missing the train?
Agree re HDCs being huge asset and most likely more effective than ganetespib. But they are slow to develop them because of cash drain of more advanced trials using ganetespib. Would love to see partnership so they have the cash to fast track HDCs
it now has attention. its great to find a biotech related stock that isnt dependent on a single FDA filing. i plan to add more on dips. They did refinancing in the 4's.
she profits big time if stock fills gap at $4+. co goal is to become profitable at lower cost structure, then grow sales and profits.
agree with shot term upside if AML is positive. i think equivalent risk on downside if results are negative. just as some euphoric longs buy at top BB, some fearful longs sell near bottom BB as do some euphoric shorts.
it should hit 4 or lower for P&F chart, then its poised to either breakdown or break out . when is difficult to say (WAG 1 to 3 mos). in the interim the BBs rule
Ericknl , PCYC went from $1 to over $100 without income producing drug. They were almost broke. Their key was angel investor and positive P1 and P2 results which attracted partner (Janssen) who provided huge upfront payment along with milestone payments that made the development process cash flow positive (they ultimately received FDA approval). Thus far SNTA does not have partner. I think AML-LI results are the key. If positive they may be enough to land a partner. If positive I expect two point pop and then huge pop when partner is arranged. If negative your target may be reached. If positive, imo first step on way to ten bagger. Sooner or later (WAG 1-3 months) we break out of range. Right now BBs are sufficiently far apart to suggest we stay in range. Thus far the winners have been the BB traders. All imo
hope springs eternal. unfilled gap around 5. 5 1/2 yrs ago KOG was 0.30. i'd love to see them aggressively drill in Ks and then branch out to Bakken.